The No Kill Zone: The Other Side of Pharma Acquisitions

CPI Antitrust Chronicle

"For decades, the US Federal Trade Commission has used various weapons in its enforcement arsenal to challenge acquisitions by incumbents of pharmaceutical products under development – so-called 'pipeline products.' A competitive concern articulated in these cases is that in pharmaceutical markets with few current competing products, and few products under development, the combined firm’s incentive to continue to develop the pipeline product may be diminished."

Read the article

Related Contacts
Jacqueline Grise Partner, Washington, DC
David Burns Associate, Washington, DC
Related Practices & Industries

Antitrust & Competition Life Sciences